rs10165970
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
rs1034925236
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our findings suggest the PPARγ P12A GG genotype and NR5A2 variants may reduce the risk for pancreatic cancer.
|
21357378 |
2011 |
rs1037189404
|
|
Pancreatic carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Spontaneous mouse model of PC (K-ras(G12D); Pdx-1cre) showed early expression of Ncoa3 during pre-neoplastic lesions.
|
25531332 |
2015 |
rs1037189404
|
|
Pancreatic carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In the present study, we have evaluated stage specific expression patterns of mucins during mouse PC progression in (Kras(G12D);Pdx1-Cre (KC)) murine PC model from pancreatic intraepithelial neoplasia (PanIN) to pancreatic ductal adenocarcinoma (PDAC) by immunohistochemistry and quantitative real-time PCR.
|
23102107 |
2012 |
rs1042522
|
|
Pancreatic carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Carriers of the variant C allele of rs1042522 polymorphism were at an increased risk of pancreatic cancer [odds ratio (OR) 1.73; 95% confidence interval (CI) 1.26-2.39; P = 0.001].
|
20110284 |
2010 |
rs1042522
|
|
Pancreatic carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
The TP53 Arg 72 Pro polymorphism has been reported to be a risk factor for several types of cancer, but its association with pancreatic cancer has not been fully evaluated.
|
21468597 |
2011 |
rs1042522
|
|
Pancreatic carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
This meta-analysis suggests that Pro allele in P53 Arg72Pro is significantly associated with the increased risks of digestive tract cancers, especially for Asians, and for gastric cancer, colorectal cancer and gallbladder and pancreatic cancer.
|
21376265 |
2011 |
rs1045485
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
CASP8 rs1045485 [odds ratio (OR), 0.78; 95% confidence interval (95% CI), 0.65-0.9; P = 0.005] and MAP3K1 rs889312 (OR, 0.85; 95% CI, 0.74-0.97; P = 0.017) showed evidence of association with risk of pancreatic cancer.
|
19843670 |
2009 |
rs104894094
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
As compared with the general population, the risk of pancreatic cancer (PC) was increased 9.4-fold [95% confidence interval (CI) 2.7-33.4] and 2.2-fold (95% CI 0.8-5.7) in G101W-positive and -negative MF, respectively, while mean ages at onset were 61 and 77 years, respectively.
|
14679123 |
2004 |
rs104894230
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors.
|
31227505 |
2019 |
rs1049074086
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D.
|
17875703 |
2007 |
rs1051730
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that 2 risk single nucleotide polymorphisms reported in the lung cancer GWA studies-rs8034191: A>G and rs1051730: G>A, located in this 15q24-25.1 region-were not associated with risk of pancreatic cancer.
|
21697764 |
2011 |
rs10519097
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
rs1052133
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
This meta-analysis suggests that the OGG1 Ser326Cys polymorphism may not associated with PC susceptibility.
|
24186001 |
2014 |
rs1053004
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In conclusion, the current study provided evidence that rs1053004 T > C in 3'UTR of STAT3 may decrease the risk of PC through up-regulating the gene expression.
|
27577070 |
2016 |
rs1053005
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We first explored the associations between two common variants (rs1053004 and rs1053005) and PC risk in 774 PC cases and 777 controls.
|
27577070 |
2016 |
rs1056836
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
All patients were followed to determine their treatment and overall survival.<br />Carriers of rare genotype Val/Val in codon 432 of CYP1B1 (rs1056836) were under significantly lower risk of pancreatic cancer than wild type carriers (p=0.035).
|
19895167 |
2010 |
rs1057519921
|
|
Pancreatic carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
K-ras<sup>LSL-G12D/+</sup>:: p53<sup>LSL-R172H/+</sup>:: Pdx-1-Cre (KPC) mice are an established model of pancreatic cancer that specifically express mutants of both K-ras and p53 in the pancreas by using Pdx-1-Cre.
|
28971839 |
2018 |
rs1057519921
|
|
Pancreatic carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Oncogene-directed increased expression of Nrf2 is a new mechanism for the activation of the Nrf2 antioxidant program, and is evident in primary cells and tissues of mice expressing K-Ras(G12D) and B-Raf(V619E), and in human pancreatic cancer.
|
21734707 |
2011 |
rs10741657
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
For example, pancreas cancer risk was inversely associated with CYP2R1 rs10741657 (AA versus GG, OR = 0.70; 95%CI: 0.51-0.95) and positively with CYP24A1 rs6127119 (TT versus CC.OR = 1.94; 95%CI: 1.28-2.94).
|
23826131 |
2013 |
rs10887710
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
When both stages were combined, we observed suggestive associations with PanCa for rs10887710 (MAT1A) (OR 1.13, 95 %CI 1.04-1.23), rs1552462 (SYT9) (OR 1.27, 95 %CI 1.02-1.59), and rs7074891 (CUBN) (OR 1.91, 95 %CI 1.12-3.26).
|
23334854 |
2013 |
rs11039149
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The glucose-raising allele of MADD rs11039149 was associated with increased risk of pancreatic cancer (OR = 1.14; CI: 1.03-1.27).
|
21445555 |
2011 |
rs11085754
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Intriguingly, gene-environmental interactions analysis consistently revealed the potential interactions of rs2073389 (P(add) - FDR = 6.00 × 10(-4), P(mul) - FDR = 1.50 × 10(-2)) and rs11085754 (P(add) - FDR = 0.03) collaborating with smoking to modify the risk of PC.
|
24585446 |
2015 |
rs111033565
|
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
HP patients with the p.R122H mutation have a 35% lifetime risk of developing pancreatic cancer, but the oncogenetic process remains unknown.
|
18946221 |
2008 |
rs111966833
|
|
Pancreatic carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
The N34S and P55S mutations were determined by PCR amplification followed by solid-phase minisequencing in 116 patients with CP and in 188 with pancreatic cancer.
|
15764155 |
2005 |